

# Index

Page numbers followed by f indicate figures; t, tables.

## A

### Acinar cells

- misinterpretation of, 49–52
- normal, 41, 43–44, 48
- oncocytic, 45
- three types of, 45–48

### Acinic cell carcinoma

- in algorithm, 132f
  - clinical management and prognosis in, 157
  - comparison table with, 151t
  - cytologic features of, 144–149
  - dedifferentiated, 200f
  - as differential diagnosis, 152, 153f, 248
  - four histologic types of, 135
  - MRI of, 22f
  - vs. normal acinic cells, 51
  - vs. oncocytomas, 150, 151t
  - overview of, 134–135
  - prevalence of, 11t
  - specific vs. descriptive diagnosis in, 7t
  - in WHO nomenclature, 11t
- ### Adenocarcinomas
- specific vs. descriptive diagnosis in, 7t
  - in WHO nomenclature, 11t

### Adenoid cystic carcinoma

- in algorithm, 82f
  - clinical management and prognosis in, 113
  - cytologic features of, 84, 97–102
  - in Diff-Quik staining, 27f
  - differential diagnosis of, 102–106, 125–128
  - matrix in, 97–101
  - overview of, 83–85
  - vs. pleomorphic adenoma, 103–104, 126, 127f
  - prevalence of, 11t
  - specific vs. descriptive diagnosis in, 7t
  - subtypes of, 84, 97–102
  - vs. epithelial-myoepithelial carcinoma, 245, 246f, 247
  - in WHO nomenclature, 11t
- ### Adenosis, sclerosing polycystic,
- 175–176
- ### Adenosquamous carcinoma,
- 195, 197
- ### AJCC. *See* American Joint Committee on Cancer (AJCC).

## Algorithms

- acinic cell carcinoma in, 132f
  - adenoid cystic carcinoma in, 82f
  - for approach to salivary gland
    - FNA, 30f, 31f
  - basal cell adenocarcinoma in, 116f
  - basaloid neoplasms in, 116f
  - carcinoma ex pleomorphic adenomas in, 184f
  - cellular lesions in, 30f, 42f, 116f, 132f, 184f
  - clear cell tumors in, 234f
  - cystic and mucinous lesions in, 31f, 160f
  - epithelial-myoepithelial carcinoma in, 234f
  - high-grade carcinomas in, 184f, 186–187
  - inflammatory cell patterns in, 31f, 58f
  - lipomas in, 42f
  - lymphoma, primary in, 58f
  - matrix-containing tumors in, 82f
  - mucocèles in, 160f
  - mucoepidermoid carcinoma in, 132f, 160f, 184f
  - for normal salivary gland aspirate, 41, 42f, 58f
  - oncocytomas in, 132f
  - parotid glands in, 42f
  - salivary duct carcinoma in, 184f
  - schwannomas (neurilemmomas) in, 204f
  - sialadenosis in, 42f
  - spindle cell tumors in, 204f
  - spindled myoepitheliomas in, 204f
  - for treatment options, 24
  - Warthin tumor in, 132f
- American Joint Committee on Cancer (AJCC) stage groupings, 14–15

- Amylase crystalloids, 65–66
- Apocrine changes, 175–176
- Artifacts of fixation and staining, 33
- Asbestos exposure, 12
- Aspiration. *See* Fine-needle aspiration (FNA).
- Atypical specimens, 39

**B**

- B-cell lymphoma, 70–74
- Bacteria. *See also specific bacteria.*
  - sialoadenitis-related, 57
- Basal cell adenocarcinoma
  - in algorithm, 116f
  - ancillary techniques in, 129
  - basaloid cells in, 121f
  - compared to adenoma, 117–118, 120
  - differential diagnosis of, 125–128
  - overview of, 117
  - in WHO nomenclature, 11t
- Basal cell adenoma
  - in algorithm, 116f
  - ancillary techniques in, 129
  - basaloid cells in, 121f, 122f
  - compared to adenocarcinoma, 117–118, 120
  - differential diagnosis of, 125–128
  - overview of, 115
  - specific vs. descriptive diagnosis in, 7t
  - three subtypes of, 115, 118–124
  - in WHO nomenclature, 11t
- Basal cell carcinoma, 243, 244f, 245f
- Basaloid neoplasms
  - in algorithm, 116f
  - ancillary techniques in, 129
  - basaloid cells in, 120f, 121f
  - clinical management and prognosis in, 129
  - cytologic features of, 74–75, 97–102
  - diagnosis of, 118–124

- diagnostic challenge in, 6  
 as differential diagnosis, 104–105  
 differential diagnosis of, 125–128  
 fine-needle aspiration (FNA) for, 120t  
 overview of, 115–118
- Benign mixed tumor. *See* Pleomorphic adenoma.
- Benign tumors. *See specific tumors.*
- Bleeding diathesis, 2
- Blood supply to salivary glands, 18–19
- Brachial cleft cysts, 176–179
- Brooke-Spiegler syndrome, 12, 117
- C**
- Calculi. *See* Sialolithiasis.
- Calponin, 214t, 215t, 222t, 223t
- Canalicular adenoma, 11t
- Carcinoma *ex* pleomorphic adenomas  
 in algorithm, 184f  
 ancillary techniques in, 199–200  
 clinical management and prognosis in, 201  
 cytologic features of, 194  
 diagnostic workup/diagnosis for, 191–194  
 differential diagnosis of, 193–197  
 overview of, 183, 185–186  
 specific vs. descriptive diagnosis in, 7t
- Carcinomas. *See also* Neoplasms, malignant salivary; *specific carcinomas.*  
 high-grade. *See* High-grade carcinomas.  
 specific vs. descriptive diagnosis in, 7t
- Carcinosarcomas, 11t
- CD117 gene, 110–111
- CD99 gene, 222t, 223t, 229  
 in spindle cell tumors, 214t, 215t
- Cell block staining, 28
- Cells. *See also specific cells.*  
 cytoplasm of. *See* Cytoplasm components.  
 in normal aspirate, 41–48  
 nuclei of. *See* Nuclei.
- Cellular lesions. *See also specific lesions.*  
 in algorithm, 30f, 42f, 82f, 116f, 132f, 184f, 204f  
 defined, 33–34
- Children, tumor types in, 10
- Chromium exposure, 12
- Clear cell carcinoma as differential diagnosis, 247–248
- Clear cell tumors  
 in algorithm, 234f  
 ancillary techniques in, 250–251  
 clinical management and prognosis in, 251–252  
 diagnostic challenge in, 6  
 diagnostic workup/diagnosis for, 236–245  
 differential diagnosis of, 245–250  
 overview of, 233–236  
 in WHO nomenclature, 11t
- Computed tomography (CT) scanning  
 combined with FNA, 22  
 usefulness and cost-effectiveness of, 21–22
- Cost-effectiveness  
 of CT scanning, 21–22  
 of fine-needle aspiration, 3
- Cribriform subtypes, 84, 97–102, 195
- Crystalloids  
 amylase type of, 65–66  
 tyrosine-rich type of, 96
- CT of. *See* Computed tomography (CT) scanning.

- Cystadenocarcinoma, 11t, 180
- Cystadenomas, 11t, 179–180
- Cystic lesions. *See also specific lesions.*
- in algorithm, 31f, 160f
  - ancillary techniques in, 180
  - clinical management and prognosis in, 180–181
  - defined, 34
  - diagnostic workup/diagnosis for, 162–172
  - differential diagnosis of, 172–180
  - general features of, 163
  - mucinous, 159–175
  - nondiagnostic or unsatisfactory, 32
  - nonmucinous, 176–180
  - in pleomorphic adenoma, 174
- Cytopathology. *See also Specific neoplasms.*
- reporting of. *See Reports, cytopathology.*
  - salivary gland challenges in, 6
- Cytoplasm components
- granularity of, 192f
  - in MALT lymphoma, 72f
  - in normal aspirate, 45–48
  - psammoma bodies in, 146, 147f
  - vacuoles, 46–47, 145–146, 148, 192f, 246f, 249f
  - zymogen granules in, 144–146, 147f, 148
- D**
- Desmin, 214t, 215t, 222t, 223t
- Diagnostic workup/diagnosis
- for carcinoma ex pleomorphic adenomas, 191–194
  - categories in, 49
  - for clear cell tumors, 236–245
  - for cystic lesions, 162–172
  - cytopathologic challenges in, 5–6
  - diagnostic categories in, 39–40
  - differential. *See Differential diagnoses.*
  - for epithelial-myoepithelial carcinoma, 237–241
  - for high-grade mucoepidermoid carcinomas, 190–191
  - for inflammatory patterns, 61–70
  - for lymphomas, 70–74
  - for oncocytomas, 135–137
  - reporting of, 34–39
  - for salivary duct carcinoma, 187–189
  - for schwannomas (neurilemmomas), 210–212
  - specific vs. descriptive, 7t
  - for spindle cell tumors, 207–213
  - for spindled myoepitheliomas, 207–209
  - steps in, 19–23
  - for Warthin tumor, 137–143
- Diff-Quik staining, 26, 27f
- Differential diagnoses
- of adenoid cystic carcinoma, 102–106
  - of carcinoma ex pleomorphic adenomas, 193–197
  - of clear cell tumors, 245–250
  - of cystic lesions, 172–180
  - of epithelial-myoepithelial carcinoma, 245–247
  - of high-grade salivary gland tumors, 193–197
  - of LESA, 76
  - of lymphoid lesions, 60–61
  - of MALT, 77–78
  - of matrix-containing tumors, 102–106
  - of mucoepidermoid carcinoma, 172–176
  - of normal aspirate, 49–55

of salivary duct tumors, 193, 195  
 sampling errors and, 49  
 of schwannomas (neurilemmomas), 213–216  
 of sialoadenitis, 74–78  
 of small cell carcinoma, 197–199  
 of spindle cell tumors, 213–229  
 of spindled myoepitheliomas, 213–216

Diffuse large B-cell lymphoma (DLBCL)  
 cytologic features of, 72–74  
 vs. MALT, 77–79  
 as percent of primary tumors, 61  
 in WHO nomenclature, 11t

Ductal cells, 41, 43–44, 47–48, 169–170  
 in acinic cell carcinoma, 148f  
 in chronic sialoadenitis, 64f, 65f

Ductal papillomas, 11t  
 as differential diagnosis, 174–175

**E**

Embryology, salivary gland, 17  
 Epidermoid cells, 166, 167f  
 Epithelial component, 90  
 Epithelial-myoepithelial carcinoma  
 vs. adenoid cystic carcinoma, 245, 246f, 247  
 in algorithm, 234f  
 clinical features of, 235  
 cytologic features of, 237–241  
 diagnostic workup/diagnosis for, 237–241  
 differential diagnosis of, 245–247  
 overview of, 233, 235  
 in WHO nomenclature, 11t

Epithelial salivary gland tumors, 76  
 Extravasation mucocoeles, 161

**F**

Facial nerves, 18f  
 False positive and false negative results, 7–8  
 Fibrillar metachromic matrix, 90f, 191  
 Fibroadipose tissue, 41, 43f, 44  
 Fibromatosis, 215t, 218, 219f  
 Fine-needle aspiration (FNA)  
 anatomic considerations in, 17–19  
 for basal cell tumors, 120t  
 benefits of, 3  
 clinical considerations in, 19–24  
 complications of, 4–5  
 for cystic lesions, 159, 161  
 equipment for, 24–25  
 false positive and false negative results in, 7–8  
 histologic changes secondary to, 4–5  
 history of, 1–2  
 indications and contraindications to, 2  
 overview of, 23  
 for pleomorphic adenomas, 83, 186  
 reporting of, 34–39  
 specificity ranges of, 7  
 specimen processing in, 25–28  
 technical considerations in, 24–26

Flow cytometry, 74–75, 78  
 FNA. *See* Fine-needle aspiration (FNA).  
 Frozen section, 8

**G**

Gender-related incidence and prevalence, 13  
 Genes  
 CD117 gene, 110–111  
 CD99 gene. *See* CD99 gene.  
 PLAG1 gene, 110  
 Goblet cells/mucin, 195

- Granular cytoplasm, 192f
- Granulomas as differential diagnosis, 215t, 216, 217f
- Granulomatous sialoadenitis, 59, 62, 66–68
- H**
- Haemophilus influenzae*, 57
- Hamartomas as differential diagnosis, 48–49, 53–54
- Head and neck metastatic squamous cell carcinoma, 174, 175f, 178, 195, 241–243, 252
- Hemangioma, 11t
- High-grade carcinomas  
in algorithm, 184f, 186–187  
ancillary techniques in, 199–200  
clinical management and prognosis in, 200–201  
diagnostic challenge in, 6  
diagnostic workup/diagnosis for, 186–194  
differential diagnosis of, 194–199  
metastatic exclusion in, 197  
overview of, 183–187
- High-grade mucoepidermoid carcinomas  
in algorithm, 184f  
cytologic features of, 191  
diagnostic workup/diagnosis for, 190–191, 195–197  
oncocytic variant of, 192f
- Histiocytes, 165, 169, 171f
- Human immunodeficiency virus (HIV) infection, 76, 178
- Hyaline cells, 87f
- Hypocellular aspirates, 163, 164f, 171f, 179f
- I**
- Imaging studies overview, 20–23
- Immunohistochemistry analysis for clear cell tumors, 250–251
- for DLBCL, 74–75  
disease-specific, 251, 252t  
for lymphomas, 61–62  
for MALT and LESA, 69, 71, 77–78  
for pleomorphic adenomas, 106  
for small cell carcinomas, 198–200  
for spindle cell tumors, 213, 229
- Immunoprofile  
of MALT, 71–72  
of matrix-containing tumors, 109–111  
of pleomorphic adenoma, 106
- Infarction of salivary tumors, 4–5
- Infection/s  
post FNA, 4–5  
of skin, 2
- Inflammatory cell patterns  
in algorithm, 31f, 58f  
ancillary techniques in, 78  
defined, 34  
diagnostic workup/diagnosis for, 61–70  
overview of, 57–60
- Intermediate cells, 166, 168f, 169
- Ionizing radiation, 11–12
- K**
- Keratin pearl formation. *See also specific tumors.*  
in pleomorphic adenoma, 94–95  
in spindle cell tumors, 214t, 215t, 222t, 223t
- KIT gene, 110–111
- Kuttner's tumor (severe chronic sclerosing sialadenitis), 59, 75
- L**
- Large cell carcinoma, 11t
- Leiomyomas, 214t, 220

- LESA. *See* Lymphoepithelial sialoadenitis (LESA).
- Light chain restriction analysis, 78
- Lipomas  
 in algorithm, 42f  
 as differential diagnosis, 49, 53
- Lymph nodes  
 parotid-associated, 235, 237  
 reactive, 7t  
 in TNM classification, 15
- Lymphadenoma, 11t
- Lymphadenopathy, 14–15
- Lymphocytes  
 background of, 65f, 67f, 73f, 76–77  
 in DLBCL, 73f  
 in MALT lymphoma, 71f  
 in normal aspirate, 44, 45, 47, 61  
 in Warthin tumor, 139f, 140–141
- Lymphoepithelial carcinoma, 11t
- Lymphoepithelial cysts, 176–179
- Lymphoepithelial sialoadenitis (LESA)  
 cystic type of, 178  
 cytologic features of, 68–69, 70f, 75  
 differential diagnosis of, 76  
 vs. MALT, 69–71, 75–76, 79  
 overview of, 60–61
- Lymphohistiocytic aggregates, 138, 140, 177, 179
- Lymphoid lesions  
 diagnostic challenge in, 6  
 differential diagnosis of, 60–61
- Lymphoma, primary  
 in algorithm, 58f  
 ancillary techniques in, 78  
 cytologic features of, 70–74  
 diagnostic workup/diagnosis for, 70–74  
 excluding possibility of, 34  
 overview of, 60–61  
 specific vs. descriptive diagnosis in, 7t
- M**
- Magnetic resonance imaging (MRI)  
 contraindications to, 22  
 usefulness and cost-effectiveness of, 22–23
- Malignancy. *See* Neoplasms, malignant salivary; *specific neoplasms*.
- Malignant peripheral nerve sheath tumors (MPNST), 223t, 225–228
- MALT. *See* Mucosa-associated lymphoid tissue (MALT) tumors.
- Matrix-containing lesions. *See also specific lesions*.  
 in algorithm, 82f  
 ancillary techniques in, 109–111  
 clinical management and prognosis in, 112–113  
 cytologic features of, 90–91, 92f  
 diagnostic challenge in, 6, 84–102  
 differential diagnosis of, 102–109  
 fibrillary metachromatic matrix, 90f, 191, 195  
 pleomorphic, 193f  
 types of, 81–84
- Melanomas  
 malignant (non-spindle), 225, 243f, 244f, 252  
 spindled malignant, 222t, 224–225, 226f
- Membranous subtypes of basal cell adenoma, 115, 117, 119, 121, 123, 124f, 126

- Metastatic disease  
 cytologic features of, 241–245  
 most common forms of, 235  
 in TNM classification, 15
- Mortality rates. *See also under specific tumors*  
 general, 13–14
- MPNST. *See* Malignant peripheral nerve sheath tumors (MPNST).
- Mucin/goblet cells, 195
- Mucinous acinar cells, 45–48
- Mucinous cysts, 159–175
- Mucinous metaplasia, 142–143
- Muciphages, 165, 169, 171f
- Mucoceles  
 in algorithm, 160f  
 clinical management and prognosis in, 180–181  
 cytologic features of, 172  
 extravasation mucoceles, 161  
 hypocellular aspirates of, 163, 164f, 171f  
 vs. mucoepidermoid carcinoma, 172  
 overview of, 161, 169–172  
 specific vs. descriptive diagnosis in, 7t
- Mucoepidermoid carcinoma  
 in algorithm, 132f, 160f, 184f  
 ancillary techniques in, 199–200  
 clinical management and prognosis in, 201  
 cytologic features of, 74–75  
 as differential diagnosis, 152, 153f  
 grading of, 162  
 high-grade. *See* High-grade mucoepidermoid carcinomas.  
 low-grade  
 clinical management and prognosis in, 180–181  
 cytologic features of, 164–169  
 differential diagnosis of, 172–176  
 three epithelial cell types in, 164–169  
 oncocytic variant of, 169, 170f, 192f  
 overview of, 161–162, 183, 185  
 prevalence of, 11t  
 vs. retention cysts and mucoceles, 172  
 specific vs. descriptive diagnosis in, 7t  
 in WHO nomenclature, 11t
- Mucosa-associated lymphoid tissue (MALT) tumors  
 differential diagnosis of, 77–78  
 vs. DLBCL, 77–79  
 immunoprofile of, 71–72  
 vs. LESA, 69–71, 75–76, 79  
 as percent of primary tumors, 61  
 in WHO nomenclature, 11t
- Mucus cells/goblet cells, 166, 167f
- Myoepithelial carcinomas, 221–222, 224
- Myoepithelial cells  
 cytologic features of, 89  
 in normal aspirate, 44f  
 of pleomorphic adenoma, 85–96, 105–106
- Myoepitheliomas  
 spindled. *See* Spindled myoepitheliomas.  
 in WHO nomenclature, 10t, 11t
- N**
- Neck dissection, modified, 181
- Necrosis of salivary tumors, 4–5
- Needle rinsings, 25, 28
- Needle track seeding, 4
- Neoplasms, benign salivary in WHO nomenclature, 10t

- Neoplasms, malignant salivary. *See also specific neoplasms.*  
 anatomy of, 17–19  
 clinical management of, 23  
 diagnosis of, 19–23  
 FNA and. *See* Fine-needle aspiration (FNA).  
 high-grade. *See* High-grade carcinomas.  
 histologic types of, 10–11  
 incidence and prevalence of, 8–9  
 patient population and presentation in, 12–13  
 prognosis for, 13–15  
 risk factors for, 11–12  
 treatment of, 24  
 WHO nomenclature for, 11t
- Nerves, facial, 18f
- Neurofibromas, 214t
- Neurofibromatosis (NF-1), 226
- Nickel alloy exposure, 12
- “No malignant cells identified”  
 diagnosis, 38
- Nodular fasciitis as differential diagnosis, 215t, 216–218
- Nondiagnostic specimens, 38
- Nuclei  
 atypical, 190f  
 bland, 248f, 249f  
 eccentric, 246f  
 elongated, 209f  
 hyperchromatic, 188f  
 multinucleated, 87f  
 palisading, 210f, 211  
 pleomorphic, 189f  
 round eccentric nuclei, 45–47, 140f  
 wavy, 212f
- O**
- Oncocytes  
 characteristics of, 131–133  
 in Warthin tumor, 139f, 141
- Oncocytic changes. *See also*  
 Oncocytic tumors.  
 cellular, 45  
 in pleomorphic adenoma, 92–95
- Oncocytic tumors  
 in algorithm, 132f  
 ancillary techniques in, 156  
 carcinoma as, 152–154  
 characteristics of, 131, 133  
 clinical management and prognosis in, 157  
 diagnosis of, 135–149  
 diagnostic challenge in, 6  
 differential diagnosis of, 150–156  
 specific vs. descriptive diagnosis in, 7t  
 in WHO nomenclature, 11t
- Oncocytomas  
 vs. acinic cell carcinoma, 150, 151t  
 in algorithm, 132f  
 clinical management and prognosis in, 157  
 comparison table with, 151t  
 cytologic features of, 136  
 diagnosis of, 136–137  
 overview of, 133
- Oncocytosis, 154–155
- P**
- Papanicolaou staining, 26, 90–91, 98–99
- Papillary cystic subtypes, 145f, 195
- Parasialomas, 8–9
- Parotid gland  
 accessory gland tissue of, 51  
 accessory gland tissue pf, 49  
 in algorithm, 42f  
 anatomy of, 17–19  
 brachial cleft cysts of, 176–179  
 cystic lesions in, 159

- Parotid gland (*cont.*)
- epithelial-myoeithelial carcinoma of, 233–236
  - lipomas of, 53
  - malignant spindle cell tumors
    - in, 222t, 224
  - normal, 43f
  - pleomorphic adenomas of, 83
  - polycystic disease of, 178–179
  - small cell carcinoma of, 197, 198f
  - tumor incidence in, 9–10
- PAS positive, diastase-resistant
  - zymogen granules, 45, 47, 134–135, 144–148
- Patients, uncooperative or agitated, 2
- Pediatrics. *See* Children.
- Phosphotungstic acid-hematoxylin (PTAH), 150, 151
- Physical examination, 20
- PLAG1 gene, 110
- Pleomorphic adenoma vs. adenoid cystic carcinoma, 103–104, 126, 127f
- in algorithm, 85
  - ancillary techniques in, 229–230
  - clinical management and prognosis in, 112–113, 230–231
  - clinicopathologic features of, 186
  - CT of, 21f
  - cystic type of, 174
  - cytologic features of, 84–96, 93–95
  - in Diff-Quik staining, 27f
  - as differential diagnosis, 205–206
  - differential diagnosis of, 125–128
  - FNA accuracy for, 7
  - immunoprofile of, 106
  - matrix-predominant, 90–91
  - with metaplastic and other changes, 92–95
  - myoepithelial-predominant, 105–106, 203–210, 229–230
  - with oncocytic features, 154
  - overview of, 81–85
  - presentation of, 83
  - prevalence of, 11t
  - specific vs. descriptive diagnosis
    - in, 7t
    - in WHO nomenclature, 10t, 11t
- PLGA. *See* Polymorphous low-grade adenocarcinoma (PLGA).
- Polycystic disease of parotid gland, 178–179
- Polymorphous low-grade adenocarcinoma (PLGA)
  - cytologic features of, 106–109
  - as differential diagnosis, 128
  - in WHO nomenclature, 11t
  - “Positive for malignant cells” diagnosis, 39–40
- Psammmoma bodies, 146, 147f
- PTAH. *See* Phosphotungstic acid-hematoxylin (PTAH).
- R**
- Radiation therapy
  - for cystic lesions, 181
  - as risk factor, 11–12
  - sialoadenitis after, 59, 74
  - for spindle cell tumors, 230
- Ranula, 161
- Renal cell carcinoma, metastatic, 155f, 156, 243, 245, 246f
- Reports, cytopathology
  - components of, 34–35
  - diagnostic categories in, 39–40
  - general interpretation categories
    - in, 35t, 37–39
  - negative or atypical, 36t
  - positive results in, 37t
  - template for, 35t

Retention cysts, 169–170, 172  
 Romanowsky staining, 90–91,  
 98–99

Rubber manufacturing, 12

## S

S-100 markers

in epithelial-myoeplithelial  
 carcinoma, 250

in spindle cell tumors, 213,  
 214t, 215t, 218, 222t,  
 223t, 229

Saliva production, 17

Salivary duct carcinoma

in algorithm, 184f, 187–189

ancillary techniques in, 199–200  
 clinical management and  
 prognosis in, 200

clinicopathologic features of, 185

cytologic features of, 187–189

diagnostic workup/diagnosis  
 for, 187–189

differential diagnosis of, 193, 195  
 overview of, 183

vacuoles in, 189f

in WHO nomenclature, 11t

Salivary glands

aspiration of. *See* Fine-needle  
 aspiration (FNA).

calculi of. *See* Sialolithiasis.

diagnostic cytopathology  
 challenges in, 5–6

inflammation of. *See* Inflamma-  
 tory cell patterns.

major vs. minor, 17

matrix-containing tumors of.  
*See* Matrix-containing  
 lesions.

neoplasia of. *See* Neoplasms,  
 malignant salivary.

normal

acinar cell features in, 45–49  
 in algorithm for, 41, 42f

clinical management of,  
 54–55

comparison table of, 151t

differential diagnosis for,  
 49–55

tissue slides of, 43f, 44f, 46f

secondary tumors of

in algorithm, 234f

clinical features of, 236

clinical management and  
 prognosis in, 252

overview of, 235

types and locations of, 9–10

Sampling errors, 41, 42f, 49

Sarcoidosis, 67, 68f, 216, 217f

Sarcomas, synovial

biphasic type, 228

clinical management and  
 prognosis in, 230–231

cytologic features of, 227–228

differential diagnosis of,  
 225–226

monophasic type, 228–229

Schwannomas (neurilemmomas)

in algorithm, 204f

ancillary techniques in, 229–230

clinical management and  
 prognosis in, 230–231

clinicopathologic features of, 206

cytologic features of, 212–213

diagnostic workup/diagnosis  
 for, 210–212

differential diagnosis of,  
 213–216

Sclerosing polycystic adenosis,  
 175–176

Sebaceous carcinoma

as differential diagnosis,  
 248–250

in WHO nomenclature, 11t

Sebaceous cells, 44–45

Sebaceous lymphadenomas,  
 248–249

- Sebacous metaplasia, 94–95
- Secondary tumors. *See under*  
Salivary glands.
- Seeding, needle track, 4
- Seromucinous acinar cells, 45–48
- Sialadenosis  
in algorithm, 42f  
as differential diagnosis, 49  
overview of, 51–52
- Sialoadenitis  
acute bacterial, 57, 58f, 62–63  
chronic, 57–60, 62, 64–66,  
125–128  
clinical management and  
prognosis in, 79  
cytologic features of, 62–63,  
66–68  
as differential diagnosis, 128  
differential diagnosis of, 74–78  
granulomatous, 59, 62, 66–68  
lymphoepithelial. *See* Lym-  
phoepithelial sialoadenitis  
(LESA).  
severe chronic sclerosing  
(Kuttner's tumor), 59  
specific vs. descriptive  
diagnosis in, 7t
- Sialoblastoma, 11t
- Sialography, 20–21
- Sialolithiasis  
in algorithm, 42f, 58f  
as differential diagnosis, 49,  
52–53  
overview of, 59
- Sialomas, 8–9
- Silica dust exposure, 12
- Sjögren's syndrome, 60, 78–79,  
178
- Skin infections, 2
- Small cell carcinoma  
differential diagnosis of,  
197–199  
in WHO nomenclature, 11t
- Smoking, 12
- Solid form subtypes  
in acinic cell carcinoma, 145f  
in adenoid cystic carcinoma,  
84, 102  
of basal cell adenoma, 119–121,  
123, 124f, 126–128
- Solitary fibrous tumors, 215t,  
218–220
- Specificity ranges, 7
- Specimens  
adequacy of, 24, 29–30, 32–33,  
35–37  
of cellular lesions. *See* Cellular  
lesions.  
collection of, 25–26  
component assessment of, 33  
of cystic lesions. *See* Cystic  
lesions.  
diagnostic categories in.  
*See* Diagnostic workup/  
diagnosis.  
general interpretation categories  
for, 35t, 37–39  
of inflammatory patterns and  
lymphoma. *See* Inflamma-  
tory cell patterns;  
Lymphoma.  
processing of, 25–28
- Spindle cell tumors  
in algorithm, 204f  
ancillary techniques in, 229–230  
clinical management  
and prognosis in, 230–231  
diagnostic challenge in, 6  
diagnostic workup/diagnosis  
for, 207–213  
differential diagnoses of, 213–229  
metastatic, 230  
overview of, 203  
table of benign types, 214–215  
table of malignant types,  
222–223

- Spindled myoepitheliomas  
 in algorithm, 204f  
 ancillary techniques in, 229–230  
 clinical management and  
 prognosis in, 230–231  
 clinicopathologic features of, 205  
 cytologic features of, 210  
 diagnostic workup/diagnosis  
 for, 207–209  
 differential diagnosis of,  
 213–216  
 overview of, 203–205
- Squamous cell carcinoma  
 as differential diagnosis, 195, 196f  
 of head and neck, 174, 175f,  
 178, 195, 241–243, 252  
 in WHO nomenclature, 11t
- Squamous metaplasia, 93–96,  
 141–143
- Staphylococcus aureus*, 57
- Stenson's duct, 18–19, 59
- Sternocleidomastoid muscle, 18f
- Stones. *See* Sialolithiasis.
- Streptococcus* species, 57
- Sublingual gland, 19
- Submandibular gland  
 anatomy of, 17–19  
 secondary tumors of, 236  
 tumor incidence in, 9–10
- “Suspicious for malignant cells”  
 diagnosis, 39
- Syncope, 4–5
- Synovial sarcomas. *See* Sarcomas,  
 synovial.
- Synsialomas, 8–9
- T**
- Thin-layer (TP) preparation,  
 27–28
- TNM (tumor, nodes, mets)  
 classification, 14–15
- TP. *See* Thin-layer (TP) preparation.
- Treatment options in algorithm, 24
- Tubular subtypes, 84, 97–102
- Tubulotrabeular subtypes,  
 119–121, 123f, 126
- Tumor infarction, 4–5
- Tumor necrosis, 4–5
- Tumor staging, 14–15
- Tumor (T) in TNM classification,  
 14–15
- Tyrosine-rich crystalloids, 96
- U**
- Ultrasonography, 20–21
- Unsatisfactory specimens, 37–38
- V**
- Vacuoles  
 in acinar cell carcinomas,  
 145–146, 148  
 in high-grade carcinomas, 192f  
 in metastatic renal cell  
 carcinoma, 246f, 249f  
 in normal acinar cells, 46–47  
 in salivary duct carcinoma, 189f
- Vascular supply to salivary glands,  
 18–19
- Verocay bodies, 211, 212f
- Vimentin, 214t, 215t, 222t, 223t
- W**
- Warthin tumor  
 in algorithm, 132f  
 clinical management and  
 prognosis in, 157  
 clinicopathologic features of,  
 134  
 comparison table with, 151t  
 cytologic features of, 74–75,  
 137–140  
 diagnosis of, 137–143  
 FNA accuracy for, 7  
 gender and, 13  
 mucin in, 173

Warthin tumor (*cont.*)

- overview of, 133
- prevalence of, 11t
- risk factors for, 134
- smoking and, 12
- source of, 17
- specific vs. descriptive  
diagnosis in, 7t
- variants in, 143
- in WHO nomenclature,  
10t, 11t

Wharton's duct, 18f, 19

- sialolithiasis of, 59

Woodworking, 12

World Health Organization

- (WHO) nomenclature for  
benign salivary tumors, 10t

**Z**

Zymogen granules, 45, 47,

- 134–135, 144–146,

147f, 148